- Home
- RXRX vs URGN Comparison
RXRX vs URGN Comparison
Compare RXRX & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXRX | URGN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RXRX | URGN |
|---|---|---|
| Price | $3.52 | $34.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $7.32 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 25.0M | 824.4K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,681,000.00 | $1,128,000.00 |
| Revenue This Year | N/A | $193.48 |
| Revenue Next Year | $26.91 | $64.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.92 | N/A |
| 52 Week Low | $2.77 | $16.50 |
| 52 Week High | $6.50 | $50.81 |
Technical Indicators
Market Signals| Indicator | RXRX | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.78 | 30.95 |
| Support Level | $2.90 | $34.18 |
| Resistance Level | $3.88 | $44.27 |
| Average True Range (ATR) | 0.45 | 2.25 |
| MACD | -0.09 | -0.33 |
| Stochastic Oscillator | 4.00 | 8.78 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.